WT5
MCID: WLM018
MIFTS: 66

Wilms Tumor 5 (WT5)

Categories: Blood diseases, Cancer diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Wilms Tumor 5

MalaCards integrated aliases for Wilms Tumor 5:

Name: Wilms Tumor 5 57 19 28 5
Wilms Tumor 57 42 53 5 41
Wt5 57 19 73
Wilms Tumor and Radial Bilateral Aplasia 19 71
Wilms Tumor Susceptibility-5 57 12
Nephroblastoma 42 71
Wilms' Tumor 42 75
Hereditary Susceptibility to Wilms Tumor 5 73
Bilateral Radial Aplasia with Wilms Tumor 19
Kidney, Adenomyosarcoma, Embryonal 42
Kidney, Carcinosarcoma, Embryonal 42
Wilms Tumor, Susceptibility to 57
Kidney, Embryonal Mixed Tumor 42
Embryonal Adenosarcoma 42
Renal Cancer, Wilms 42
Embryonal Nephroma 42
Kidney Wilms Tumor 42
Renal Adenosarcoma 42
Renal Wilms Tumor 42
Kidney, Embryoma 42
Tumor, Wilms 42
Nephroma 42
Wtsl 57

Characteristics:


Inheritance:

Autosomal dominant 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
most cases are sporadic
tumor suppressor gene


Classifications:



External Ids:

OMIM® 57 601583
OMIM Phenotypic Series 57 PS194070
MedGen 40 C1832099
SNOMED-CT via HPO 69 25081006 302849000
UMLS 71 C0027708 C1832099

Summaries for Wilms Tumor 5

MedlinePlus Genetics: 42 Wilms tumor is a form of kidney cancer that primarily develops in children. Nearly all cases of Wilms tumor are diagnosed before the age of 10, with two-thirds being found before age 5.Wilms tumor is often first noticed because of abdominal swelling or a mass in the kidney that can be felt upon physical examination. Some affected children have abdominal pain, fever, a low number of red blood cells (anemia), blood in the urine (hematuria), or high blood pressure (hypertension). Additional signs of Wilms tumor can include loss of appetite, weight loss, nausea, vomiting, and tiredness (lethargy).Wilms tumor can develop in one or both kidneys. About 5 to 10 percent of affected individuals develop multiple tumors in one or both kidneys. Wilms tumor may spread from the kidneys to other parts of the body (metastasize). In rare cases, Wilms tumor does not involve the kidneys and occurs instead in the genital tract, bladder, abdomen, chest, or lower back. It is unclear how Wilms tumor develops in these tissues.With proper treatment, children with Wilms tumor have a 90 percent survival rate. However, the risk that the cancer will come back (recur) is between 15 and 50 percent, depending on traits of the original tumor. Tumors usually recur in the first 2 years following treatment and develop in the kidneys or other tissues, such as the lungs. Individuals who have had Wilms tumor may experience related health problems or late effects of their treatment in adulthood, such as decreased kidney function, heart disease, and development of additional cancers.

MalaCards based summary: Wilms Tumor 5, also known as wilms tumor, is related to frasier syndrome and metanephric adenoma, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 5 is POU6F2 (POU Class 6 Homeobox 2), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers and Primary focal segmental glomerulosclerosis (FSGS). The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, myeloid and t cells, and related phenotypes are nephroblastoma and embryo

MedlinePlus: 41 Wilms tumor is a rare type of kidney cancer. It causes a tumor on one or both kidneys. It usually affects children, but can happen in adults. Having certain genetic conditions or birth defects can increase the risk of getting it. Children that are at risk should be screened for Wilms tumor every three months until they turn eight. Symptoms include a lump in the abdomen, blood in the urine, and a fever for no reason. Tests that examine the kidney and blood are used to find the tumor. Doctors usually diagnose and remove the tumor in surgery. Other treatments include chemotherapy and radiation and biologic therapies. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

UniProtKB/Swiss-Prot: 73 Pediatric malignancy of kidney and one of the most common solid cancers in childhood.

Wikipedia: 75 Wilms' tumor or Wilms tumor, also known as nephroblastoma, is a cancer of the kidneys that typically... more...

More information from OMIM: 601583 PS194070

Related Diseases for Wilms Tumor 5

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 972)
# Related Disease Score Top Affiliating Genes
1 frasier syndrome 32.2 WT1 PAX6 PAX2
2 metanephric adenoma 31.8 WT1 PAX2
3 hereditary wilms' tumor 31.7 WT1 TRIM28 DIS3L2
4 aniridia 1 31.7 WT1 PAX6 PAX2
5 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 31.7 WT1 PAX6 IGF2
6 denys-drash syndrome 31.7 WT1 PAX6 PAX2
7 hemihyperplasia, isolated 31.5 WT1 IGF2 H19 CDKN1C
8 wilms tumor 1 30.5 WTAP WT1 TRIM28 SLC22A18 POU6F2 PAX6
9 leiomyosarcoma 30.4 WT1 IGF2 CHEK2
10 clear cell sarcoma 30.4 WT1 IGF2 BRAF
11 renal cell carcinoma, papillary, 1 30.3 WT1 PAX2 BRAF
12 silver-russell syndrome 1 30.1 SLC22A18 IGF2 H19 CDKN1C
13 renal wilms' tumor 30.0 WT1 DIS3L2
14 sotos syndrome 30.0 IGF2 GPC3 DIS3L2 CDKN1C
15 malignant teratoma 30.0 WT1 GPC3
16 umbilical hernia 29.9 IGF2 H19 CDKN1C
17 renal hypodysplasia/aplasia 1 29.8 WT1 PAX2 IGF2
18 adrenal cortical carcinoma 29.8 IGF2 H19 CHEK2 CDKN1C BRAF
19 omphalocele 29.8 IGF2 GPC3 CDKN1C
20 embryonal rhabdomyosarcoma 29.7 WT1 SLC22A18 IGF2 H19
21 adenofibroma 29.7 WT1 BRAF
22 rhabdomyosarcoma 29.4 WT1 SLC22A18 IGF2 H19 GPC3 CHEK2
23 hepatoblastoma 29.2 WT1 SLC22A18 IGF2 H19 GPC3 CDKN1C
24 beckwith-wiedemann syndrome 29.0 WT1 SLC22A18 NAP1L4 IGF2 H19 GPC3
25 global developmental delay, lung cysts, overgrowth, and wilms tumor 11.7
26 wilms tumor 4 11.6
27 cervical wilms' tumor 11.6
28 wilms tumor 3 11.5
29 adult cystic nephroma 11.4
30 epithelial predominant wilms' tumor 11.4
31 stromal predominant kidney wilms' tumor 11.4
32 familial wilms tumor 2 11.4
33 mixed cell type kidney wilms' tumor 11.3
34 blastema predominant kidney wilms' tumor 11.3
35 cellular congenital mesoblastic nephroma 11.2
36 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 11.2
37 metachronous kidney wilms' tumor 11.2
38 mulibrey nanism 11.2
39 mosaic variegated aneuploidy syndrome 1 11.2
40 simpson-golabi-behmel syndrome, type 1 11.2
41 hyperparathyroidism 2 with jaw tumors 11.2
42 mosaic variegated aneuploidy syndrome 3 11.2
43 mosaic variegated aneuploidy syndrome 11.2
44 classic congenital mesoblastic nephroma 11.2
45 wilms tumor predisposition 11.2
46 graham boyle troxell syndrome 11.2
47 li-fraumeni syndrome 11.1
48 chromosome 2q37 deletion syndrome 11.1
49 fanconi anemia, complementation group d1 11.1
50 megalencephaly-capillary malformation-polymicrogyria syndrome 11.1

Graphical network of the top 20 diseases related to Wilms Tumor 5:



Diseases related to Wilms Tumor 5

Symptoms & Phenotypes for Wilms Tumor 5

Human phenotypes related to Wilms Tumor 5:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nephroblastoma 30 HP:0002667

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Genitourinary Kidneys:
nephroblastoma (wilms tumor)

Neoplasia:
nephroblastoma (wilms tumor)

Clinical features from OMIM®:

601583 (Updated 08-Dec-2022)

UMLS symptoms related to Wilms Tumor 5:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 5:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 10.07 BRAF CCN1 CDKN1C GPC3 IGF2 PAX2
2 renal/urinary system MP:0005367 10.06 BRAF CCN3 CDKN1C DIS3L2 GPC3 IGF2
3 cellular MP:0005384 10.06 BRAF CCN1 CCN3 CDKN1C CHEK2 GPC3
4 cardiovascular system MP:0005385 10 BRAF CCN1 CCN3 CDKN1C CHEK2 GPC3
5 respiratory system MP:0005388 9.7 BRAF CDKN1C DIS3L2 GPC3 IGF2 PAX6
6 reproductive system MP:0005389 9.65 BRAF CCN3 CDKN1C CHEK2 GPC3 IGF2
7 mortality/aging MP:0010768 9.44 BRAF CCN1 CCN3 CDKN1C CHEK2 DIS3L2

Drugs & Therapeutics for Wilms Tumor 5

Drugs for Wilms Tumor 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
4
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
5
Dactinomycin Approved, Investigational Phase 4 50-76-0 2019 457193
6
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
7
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
8
Epirubicin Approved Phase 4 56420-45-2 41867
9
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 54715139 54675779
10
Pirarubicin Investigational Phase 4 72496-41-4 4844
11 Antifungal Agents Phase 4
12
Hydroxyitraconazole Phase 4 108222
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Cytochrome P-450 CYP3A Inhibitors Phase 4
15 Anti-Bacterial Agents Phase 4
16 Anti-Infective Agents Phase 4
17 Antimitotic Agents Phase 4
18 Tubulin Modulators Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Liposomal doxorubicin Phase 4
21 Alkylating Agents Phase 4
22 Antirheumatic Agents Phase 4
23 Antineoplastic Agents, Alkylating Phase 4
24 Immunosuppressive Agents Phase 4
25 Immunologic Factors Phase 4
26
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
27
Sulfamethoxazole Approved Phase 3 723-46-6 5329
28
Lenograstim Approved, Investigational Phase 3 135968-09-1
29 Hormones Phase 3
30 Liver Extracts Phase 3
31 Calcium, Dietary Phase 3
32 Cactinomycin Phase 3
33 Adjuvants, Immunologic Phase 3
34
Calcium Nutraceutical Phase 3 7440-70-2 271
35
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
36
Adenosine Approved, Investigational Phase 2 58-61-7 60961
37
Trastuzumab Approved, Investigational Phase 2 180288-69-1
38
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
39
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
40
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
41
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
42
Etanercept Approved, Investigational Phase 2 185243-69-0
43
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
44
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
45
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
46
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
47
Daunorubicin Approved Phase 2 20830-81-3 30323
48
Ivosidenib Approved, Investigational Phase 2 1448347-49-6 78140854 71657455
49
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203
50
Talazoparib Approved, Investigational Phase 1, Phase 2 1207456-01-6 135565082

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
2 A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma. Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
3 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
4 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
5 National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
6 NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
7 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
8 Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR Completed NCT00179829 Phase 2, Phase 3
9 Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
10 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor Active, not recruiting NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
11 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors Active, not recruiting NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
12 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Terminated NCT01987596 Phase 3
13 Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
14 Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial Unknown status NCT00965224 Phase 2
15 Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study Unknown status NCT01291420 Phase 1, Phase 2
16 Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
17 Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
18 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
19 A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation Completed NCT00405327 Phase 2
20 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
21 A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Completed NCT02452554 Phase 2
22 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
23 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
24 Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2 Liposomal Vincristine
25 Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Completed NCT01095926 Phase 2 doxorubicin
26 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
27 Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00309907 Phase 2 methylprednisolone
28 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
29 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
30 Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) Recruiting NCT04322318 Phase 2 Carboplatin;Cyclophosphamide;Doxorubicin;Etoposide;Ifosfamide;Irinotecan;Topotecan;Vincristine
31 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
32 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
33 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Recruiting NCT04320888 Phase 2 Selpercatinib
34 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib Sulfate
35 A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma Recruiting NCT04901702 Phase 1, Phase 2 Onivyde;Talazoparib;Temozolomide
36 Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid Tumors Recruiting NCT05302921 Phase 2 Nivolumab;Ipilimumab
37 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib Sulfate;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
38 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
39 A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting NCT04851119 Phase 1, Phase 2 Tegavivint
40 Multi-Center Trial Sponsored by St. Jude Children's Research Hospital for the Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation Recruiting NCT04968990 Phase 2 DD-4A Chemotherapy Regimen
41 First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma Recruiting NCT02649829 Phase 1, Phase 2
42 Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial Recruiting NCT01686334 Phase 2
43 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
44 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Active, not recruiting NCT03698994 Phase 2 Ulixertinib
45 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Active, not recruiting NCT03526250 Phase 2 Palbociclib
46 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Active, not recruiting NCT03233204 Phase 2 Olaparib
47 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Active, not recruiting NCT03213665 Phase 2 Tazemetostat
48 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations Active, not recruiting NCT03220035 Phase 2 Vemurafenib
49 A Pilot Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Treatment of Relapsed or Refractory Solid Tumors Not yet recruiting NCT04791228 Phase 2 Lyso-thermosensitive Liposomal Doxorubicin
50 Phase 2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor Not yet recruiting NCT05384821 Phase 1, Phase 2 Vincristine;Irinotecan;Temozolomide;Etoposide;Cis-Retinoic acid

Search NIH Clinical Center for Wilms Tumor 5

Genetic Tests for Wilms Tumor 5

Genetic tests related to Wilms Tumor 5:

# Genetic test Affiliating Genes
1 Wilms Tumor 5 28 POU6F2

Anatomical Context for Wilms Tumor 5

Organs/tissues related to Wilms Tumor 5:

MalaCards : Kidney, Myeloid, T Cells, Heart, Bone Marrow, Lung, Bone

Publications for Wilms Tumor 5

Articles related to Wilms Tumor 5:

(show top 50) (show all 10205)
# Title Authors PMID Year
1
Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. 62 57 5
15459955 2004
2
Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in Wilms tumours. 57 5
11284034 2001
3
TRIM28 congenital predisposition to Wilms' tumor: novel mutations and presentation in a sibling pair. 62 5
32699065 2020
4
Localization of a novel t(1;7) translocation associated with Wilms' tumor predisposition and skeletal abnormalities. 62 57
8946193 1996
5
Germline and somatic abnormalities of chromosome 7 in Wilms' tumor. 62 57
7954327 1994
6
Isolated lateralized overgrowth: clinical, radiological, and auxological characteristics of a single-site cohort of 76 cases. 62 41
36374059 2022
7
Nanobody-based CAR T cells targeting intracellular tumor antigens. 62 41
36411612 2022
8
Characterization of alternative mRNA splicing in cultured cell populations representing progressive stages of human fetal kidney development. 62 41
36380228 2022
9
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. 5
24723567 2014
10
Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases. 5
23415889 2013
11
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. 5
23409019 2013
12
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. 5
22811390 2013
13
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. 5
23109706 2012
14
CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families. 5
23329222 2012
15
Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. 5
22691310 2012
16
Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer. 5
22520019 2012
17
A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations. 5
22058216 2012
18
CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. 5
21956126 2012
19
CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. 5
22994785 2012
20
CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. 5
22058428 2011
21
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. 5
22006311 2011
22
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. 5
21876083 2011
23
Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. 5
21244692 2011
24
Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. 5
20722467 2010
25
Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. 5
19030985 2009
26
CHEK2 1100delC and male breast cancer in the Netherlands. 5
18759107 2009
27
CHEK2 is a multiorgan cancer susceptibility gene. 5
15492928 2004
28
The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour. 57
12618763 2003
29
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. 5
11967536 2002
30
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. 5
11719428 2001
31
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. 5
10617473 1999
32
Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour. 57
9690521 1998
33
Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors. 57
8938443 1996
34
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. 53 62
20166202 2010
35
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 53 62
20435628 2010
36
Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3) by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the human trophoblast. 53 62
20237132 2010
37
Wilms tumor suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of STIM1 expression. 53 62
20123987 2010
38
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. 53 62
20332316 2010
39
Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. 53 62
20423567 2010
40
The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells. 53 62
20204298 2010
41
The CCN family proteins in carcinogenesis. 53 62
20332765 2010
42
Conditionally immortalized human podocyte cell lines established from urine. 53 62
19955187 2010
43
Integrative genomic analyses on interferon-lambdas and their roles in cancer prediction. 53 62
20043142 2010
44
Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. 53 62
19348510 2010
45
The expression of the insulin-like growth factor II, JIP-1 and WT1 genes in porcine nephroblastoma. 53 62
20044608 2009
46
High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor. 53 62
19749460 2009
47
Peptide vaccines for patients with acute myeloid leukemia. 53 62
19803762 2009
48
WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? 53 62
19530245 2009
49
Nuclear degradation of Wilms tumor 1-associating protein and survivin splice variant switching underlie IGF-1-mediated survival. 53 62
19605357 2009
50
[Unilateral renal tumor in a child: nephroblastoma concurrent with a rare form of (translocation?) renal-cell carcinoma]. 53 62
19938705 2009

Variations for Wilms Tumor 5

ClinVar genetic disease variations for Wilms Tumor 5:

5 (show all 43)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CTNNB1 NM_001904.4(CTNNB1):c.770C>T (p.Thr257Ile) SNV Other
438758 rs1553630452 GRCh37: 3:41267186-41267186
GRCh38: 3:41225695-41225695
2 CTNNB1 NM_001904.4(CTNNB1):c.133_135del (p.Ser45del) DEL Other
17576 rs587776850 GRCh37: 3:41266136-41266138
GRCh38: 3:41224643-41224645
3 TET2-AS1, TET2 NM_001127208.3(TET2):c.4456T>C (p.Ser1486Pro) SNV Other
438791 rs1553918194 GRCh37: 4:106193994-106193994
GRCh38: 4:105272837-105272837
4 MED12 NM_005120.3(MED12):c.131G>A (p.Gly44Asp) SNV Other
92220 rs199469672 GRCh37: X:70339254-70339254
GRCh38: X:71119404-71119404
5 FZD6 NM_003506.4(FZD6):c.346C>T (p.Arg116Ter) SNV Other
438765 rs769116796 GRCh37: 8:104330986-104330986
GRCh38: 8:103318758-103318758
6 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Other
17588 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
7 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
8 TRIM28 NM_005762.3(TRIM28):c.2101C>T (p.Gln701Ter) SNV Pathogenic
973190 rs2053798835 GRCh37: 19:59061222-59061222
GRCh38: 19:58549855-58549855
9 POU6F2 NM_001370959.1(POU6F2):c.660G>T (p.Gln220His) SNV Pathogenic
1871 rs121918261 GRCh37: 7:39379302-39379302
GRCh38: 7:39339703-39339703
10 POU6F2 NM_001370959.1(POU6F2):c.62C>G (p.Ser21Ter) SNV Pathogenic
1872 GRCh37: 7:39017615-39017615
GRCh38: 7:38978015-38978015
11 CHEK2 NM_007194.4(CHEK2):c.1100_1101del (p.Thr367fs) DEL Pathogenic
438773 rs1555913934 GRCh37: 22:29091856-29091857
GRCh38: 22:28695868-28695869
12 DIS3L2 NM_152383.5(DIS3L2):c.2381_2382del (p.Arg794fs) MICROSAT Likely Pathogenic
438774 rs1553551874 GRCh37: 2:233199430-233199431
GRCh38: 2:232334720-232334721
13 WT1 NM_024426.6(WT1):c.*1021GT[15] MICROSAT Uncertain Significance
304379 rs58549495 GRCh37: 11:32409550-32409553
GRCh38: 11:32388004-32388007
14 WT1 NM_024426.6(WT1):c.*707C>A SNV Uncertain Significance
304394 rs886048217 GRCh37: 11:32409897-32409897
GRCh38: 11:32388351-32388351
15 WT1, LOC107982234 NM_024426.6(WT1):c.-90T>C SNV Uncertain Significance
304435 rs886048238 GRCh37: 11:32456996-32456996
GRCh38: 11:32435450-32435450
16 WT1 NM_024426.6(WT1):c.*841C>A SNV Uncertain Significance
304388 rs886048213 GRCh37: 11:32409763-32409763
GRCh38: 11:32388217-32388217
17 WT1 NM_024426.6(WT1):c.*1021GT[19] MICROSAT Uncertain Significance
304377 rs58549495 GRCh37: 11:32409549-32409550
GRCh38: 11:32388003-32388004
18 WT1, LOC107982234 NM_024426.6(WT1):c.285C>T (p.Gly95=) SNV Uncertain Significance
304426 rs886048230 GRCh37: 11:32456622-32456622
GRCh38: 11:32435076-32435076
19 WT1 NM_024426.6(WT1):c.*1021GT[14] MICROSAT Uncertain Significance
304381 rs58549495 GRCh37: 11:32409550-32409555
GRCh38: 11:32388004-32388009
20 WT1 NM_024426.6(WT1):c.*1058G>T SNV Uncertain Significance
304376 rs886048211 GRCh37: 11:32409546-32409546
GRCh38: 11:32388000-32388000
21 WT1 NM_024426.6(WT1):c.*685G>T SNV Uncertain Significance
304395 rs886048218 GRCh37: 11:32409919-32409919
GRCh38: 11:32388373-32388373
22 WT1, LOC107982234 NM_024426.6(WT1):c.136G>T (p.Ala46Ser) SNV Uncertain Significance
304430 rs886048233 GRCh37: 11:32456771-32456771
GRCh38: 11:32435225-32435225
23 WT1, LOC107982234 NM_024426.6(WT1):c.-86T>C SNV Uncertain Significance
304434 rs886048237 GRCh37: 11:32456992-32456992
GRCh38: 11:32435446-32435446
24 WT1 NM_024426.6(WT1):c.*741G>T SNV Uncertain Significance
304393 rs886048216 GRCh37: 11:32409863-32409863
GRCh38: 11:32388317-32388317
25 WT1 NM_024426.6(WT1):c.*1021GT[20] MICROSAT Uncertain Significance
304378 rs58549495 GRCh37: 11:32409549-32409550
GRCh38: 11:32388003-32388004
26 WT1, LOC107982234 NM_024426.6(WT1):c.411GCC[5] (p.Pro141dup) MICROSAT Uncertain Significance
406690 rs760304811 GRCh37: 11:32456484-32456485
GRCh38: 11:32434938-32434939
27 SMAD4 NM_005359.6(SMAD4):c.875C>T (p.Pro292Leu) SNV Uncertain Significance
184326 rs786201404 GRCh37: 18:48584797-48584797
GRCh38: 18:51058427-51058427
28 WT1 NM_024426.6(WT1):c.*269G>T SNV Uncertain Significance
304409 rs886048225 GRCh37: 11:32410335-32410335
GRCh38: 11:32388789-32388789
29 WT1, LOC107982234 NM_024426.6(WT1):c.-31G>T SNV Uncertain Significance
304431 rs886048234 GRCh37: 11:32456937-32456937
GRCh38: 11:32435391-32435391
30 WT1, LOC107982234 NM_024426.6(WT1):c.-94G>C SNV Uncertain Significance
304436 rs886048239 GRCh37: 11:32457000-32457000
GRCh38: 11:32435454-32435454
31 WT1, LOC107982234 NM_024426.6(WT1):c.-82A>C SNV Uncertain Significance
304433 rs886048236 GRCh37: 11:32456988-32456988
GRCh38: 11:32435442-32435442
32 WT1 NM_024426.6(WT1):c.*1021GT[18] MICROSAT Uncertain Significance
304380 rs58549495 GRCh37: 11:32409549-32409550
GRCh38: 11:32388003-32388004
33 WT1 NM_024426.6(WT1):c.*574del DEL Uncertain Significance
304400 rs5030319 GRCh37: 11:32410030-32410030
GRCh38: 11:32388484-32388484
34 WT1 NM_024426.6(WT1):c.*393G>T SNV Uncertain Significance
304405 rs886048222 GRCh37: 11:32410211-32410211
GRCh38: 11:32388665-32388665
35 WT1, LOC107982234 NM_024426.6(WT1):c.247G>T (p.Ala83Ser) SNV Uncertain Significance
304427 rs886048231 GRCh37: 11:32456660-32456660
GRCh38: 11:32435114-32435114
36 WT1 NM_024426.6(WT1):c.*768A>C SNV Uncertain Significance
304392 rs886048215 GRCh37: 11:32409836-32409836
GRCh38: 11:32388290-32388290
37 WT1 NM_024426.6(WT1):c.*354G>T SNV Uncertain Significance
304407 rs886048224 GRCh37: 11:32410250-32410250
GRCh38: 11:32388704-32388704
38 WT1 NM_024426.6(WT1):c.*366C>A SNV Uncertain Significance
304406 rs886048223 GRCh37: 11:32410238-32410238
GRCh38: 11:32388692-32388692
39 WT1 NM_024426.6(WT1):c.*897G>C SNV Likely Benign
304385 rs5030324 GRCh37: 11:32409707-32409707
GRCh38: 11:32388161-32388161
40 WT1 NM_024426.6(WT1):c.*542G>A SNV Likely Benign
304401 rs142726499 GRCh37: 11:32410062-32410062
GRCh38: 11:32388516-32388516
41 WT1 NM_024426.6(WT1):c.*138G>A SNV Likely Benign
304414 rs111351882 GRCh37: 11:32410466-32410466
GRCh38: 11:32388920-32388920
42 WT1 NM_024426.6(WT1):c.*978dup DUP Benign
304383 rs5030326 GRCh37: 11:32409625-32409626
GRCh38: 11:32388079-32388080
43 WT1 NM_024426.6(WT1):c.*1049del DEL Benign
304382 rs568803808 GRCh37: 11:32409555-32409555
GRCh38: 11:32388009-32388009

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 5:

73
# Symbol AA change Variation ID SNP ID
1 POU6F2 p.Gln192His VAR_022419

Expression for Wilms Tumor 5

LifeMap Discovery
Genes differentially expressed in tissues of Wilms Tumor 5 patients vs. healthy controls: 35 (show top 50) (show all 333)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CDH16 cadherin 16 Kidney - 11.18 0.000
2 SLC12A1 solute carrier family 12 member 1 Kidney - 10.67 0.000
3 SOX11 SRY-box transcription factor 11 Kidney + 9.64 0.000
4 LYPD1 LY6/PLAUR domain containing 1 Kidney + 9.37 0.000
5 ACSM2A acyl-CoA synthetase medium chain family member 2A Kidney - 9.29 0.009
6 FXYD4 FXYD domain containing ion transport regulator 4 Kidney - 9.21 0.000
7 CALB1 calbindin 1 Kidney - 9.11 0.000
8 TOP2A DNA topoisomerase II alpha Kidney + 9.07 0.000
9 SCNN1A sodium channel epithelial 1 subunit alpha Kidney - 8.78 0.000
10 KCNJ1 potassium inwardly rectifying channel subfamily J member 1 Kidney - 8.78 0.000
11 EYA1 EYA transcriptional coactivator and phosphatase 1 Kidney + 8.66 0.000
12 EGF epidermal growth factor Kidney - 8.65 0.000
13 NAT8 N-acetyltransferase 8 (putative) Kidney - 8.65 0.001
14 COL2A1 collagen type II alpha 1 chain Kidney + 8.57 0.000
15 SMIM24 small integral membrane protein 24 Kidney - 8.35 0.000
16 MIOX myo-inositol oxygenase Kidney - 8.15 0.000
17 TMEM52B transmembrane protein 52B Kidney - 8.08 0.000
18 PDZK1IP1 PDZK1 interacting protein 1 Kidney - 8.07 0.000
19 BBOX1 gamma-butyrobetaine hydroxylase 1 Kidney - 8.04 0.000
20 ALDOB aldolase, fructose-bisphosphate B Kidney - 8.04 0.022
21 MAL mal, T cell differentiation protein Kidney - 7.98 0.000
22 ATP6V0A4 ATPase H+ transporting V0 subunit a4 Kidney - 7.93 0.000
23 KL klotho Kidney - 7.93 0.000
24 GLYAT glycine-N-acyltransferase Kidney - 7.88 0.002
25 CITED1 Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1 Kidney + 7.81 0.000
26 SIX1 SIX homeobox 1 Kidney + 7.76 0.000
27 BHMT betaine--homocysteine S-methyltransferase Kidney - 7.74 0.003
28 NPHS2 NPHS2 stomatin family member, podocin Kidney - 7.68 0.000
29 DEFB1 defensin beta 1 Kidney - 7.64 0.000
30 KLHDC7A kelch domain containing 7A Kidney - 7.60 0.000
31 OGDHL oxoglutarate dehydrogenase L Kidney - 7.52 0.000
32 CLDN8 claudin 8 Kidney - 7.44 0.000
33 CLCNKB chloride voltage-gated channel Kb Kidney - 7.43 0.000
34 HPD 4-hydroxyphenylpyruvate dioxygenase Kidney - 7.39 0.010
35 TACSTD2 tumor associated calcium signal transducer 2 Kidney - 7.38 0.000
36 FXYD2 FXYD domain containing ion transport regulator 2 Kidney - 7.32 0.000
37 TMEM45B transmembrane protein 45B Kidney - 7.31 0.000
38 SCNN1G sodium channel epithelial 1 subunit gamma Kidney - 7.30 0.000
39 MFSD4A major facilitator superfamily domain containing 4A Kidney - 7.27 0.000
40 TMEM213 transmembrane protein 213 Kidney - 7.26 0.000
41 MUC15 mucin 15, cell surface associated Kidney - 7.25 0.000
42 TFAP2B transcription factor AP-2 beta Kidney - 7.24 0.000
43 PDZK1 PDZ domain containing 1 Kidney - 7.20 0.004
44 HMGA2 high mobility group AT-hook 2 Kidney + 7.20 0.000
45 SLC13A1 solute carrier family 13 member 1 Kidney - 7.19 0.000
46 PAH phenylalanine hydroxylase Kidney - 7.16 0.018
47 FGF1 fibroblast growth factor 1 Kidney - 7.16 0.000
48 DNASE1 deoxyribonuclease 1 Kidney - 7.13 0.000
49 SLC13A3 solute carrier family 13 member 3 Kidney - 7.13 0.000
50 G6PC1 glucose-6-phosphatase catalytic subunit 1 Kidney - 7.10 0.017
Search GEO for disease gene expression data for Wilms Tumor 5.

Pathways for Wilms Tumor 5

Pathways related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.46 WT1 PAX6 PAX2
2 10.99 WT1 PAX2 CDKN1C
3 10.45 WT1 PAX2 GPC3

GO Terms for Wilms Tumor 5

Biological processes related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of epithelial cell proliferation GO:0050680 9.91 PAX6 GPC3 CDKN1C
2 animal organ morphogenesis GO:0009887 9.87 PAX6 IGF2 GPC3 BRAF
3 branching involved in ureteric bud morphogenesis GO:0001658 9.73 GPC3 PAX2 WT1
4 mesenchymal to epithelial transition GO:0060231 9.71 WT1 PAX2
5 metanephric mesenchyme development GO:0072075 9.67 WT1 PAX2
6 camera-type eye development GO:0043010 9.5 WT1 PAX6 PAX2 CDKN1C
7 metanephric epithelium development GO:0072207 9.46 WT1 PAX2
8 embryonic placenta morphogenesis GO:0060669 9.1 TRIM28 IGF2 CDKN1C

Molecular functions related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.23 IGF2 CCN5 CCN3 CCN1

Sources for Wilms Tumor 5

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....